Kornimate/medical-research-clean huggingface dataset:
bilateral dispensing study of myday toric, 1-day acuvue moist for astigmatism, and dailies aquacomfort plus toric lenses

Conditions: Astigmatism

Summary: bilateral dispensing study of myday toric, 1-day acuvue moist for astigmatism, and dailies aquacomfort plus toric lenses

prospective, double-masked (investigator and participant), bilateral, randomized, cross-over dispensing study comparing the myday toric (test) against the 1-day acuvue moist for astigmatism (control), and dailies aquacomfort plus toric (control) lenses

Eligibility criteria:
inclusion criteria: 1. is at least 17 years of age and has full legal capacity to volunteer; 2. has had a self-reported oculo-visual examination in the last two years. 3. has read and signed an information consent letter; 4. is willing and able to follow instructions and maintain the appointment schedule; 5. is an adapted soft contact lens wearer; 6. is willing to wear contact lens in both eyes for the duration of the study; 7. has a minimum spectacle astigmatism of - 0.75; 8. can be fit with the three study contact lens types in the powers available; 9. has a visual acuity of 20/30 or better in each eye with habitual correction, or 20/20 best corrected vision (for binocular distance acuity); 10. can achieve a distance visual acuity of 20/30 (0.18 logmar) or better in each eye with the study contact lenses. 11. has clear corneas and no active\* ocular disease; * for the purposes of this study, active ocular disease is defined as infection or inflammation which requires therapeutic treatment. mild (i.e. not considered clinically relevant) lid abnormalities (blepharitis, meibomian gland dysfunction, papillae), corneal and conjunctival staining and dry eye are not considered active ocular disease. neovascularization and corneal scars are the result of previous hypoxia, infection or inflammation and are therefore not active. exclusion criteria: 1. is participating in any concurrent clinical trial; 2. has any known active\* ocular disease and/or infection; 3. has a systemic condition that in the opinion of the investigator may affect a study outcome variable; 4. is using any systemic or topical medications that in the opinion of the investigator may affect a study outcome variable; 5. has known sensitivity to fluorescein dye or products to be used in the study; 6. appears to have any active\* ocular pathology, ocular anomaly or severe insufficiency of lacrimal secretion (severe dry eye) that would affect the wearing of contact lenses; 7. is pregnant, lactating or planning a pregnancy at the time of enrolment (by verbal confirmation at the screening visit); 8. is aphakic; 9. has undergone refractive error surgery.
thailand transgender women stigma study

Conditions: Pre-Exposure Prophylaxis

Summary: this project will develop a multi-component, technology-delivered intervention designed to reduce hiv and intersectional stigma and improve the use of hiv pre-exposure prophylaxis (prep) among hiv-negative thai, young transgender women (18-29 years).


Eligibility criteria:
aim 1 (formative research and beta-testing) transgender women inclusion criteria: * ages between 18 and 29 years * male sex at birth * self-identifies as women, transgender women or culturally identifies with the female spectrum * laboratory-confirmed hiv-negative status * self-reported recent history of condomless sex * able to understand, read and speak thai * either not started prep or currently on prep but not adherent (taking ≤3 pills/week) in the past month. exclusion criteria: * have a serious cognitive or psychiatric problem compromising ability to provide informed consent * have active suicidal ideation or major mental illness at the time of interview (these patients will be referred for treatment) * laboratory or clinical findings that would preclude prep initiation (e.g., decreased creatinine clearance) * currently enrolled in another hiv intervention study. healthcare providers inclusion criteria * age 18 or above * has provided hiv prevention or treatment services for tgw for at least one year exclusion criteria * none aim 2 (pilot rct) transgender women inclusion criteria * ages between 18 and 29 years * male sex at birth * self-identifies as women, transgender women or culturally identifies with the female spectrum * laboratory-confirmed hiv-negative status * self-reported recent history of condomless sex * able to understand, read and speak thai * either not started prep or currently on prep but not adherent (taking ≤3 pills/week) in the past month. exclusion criteria * have a serious cognitive or psychiatric problem compromising ability to provide informed consent * have active suicidal ideation or major mental illness at the time of interview (these patients will be referred for treatment) * laboratory or clinical findings that would preclude prep initiation (e.g., decreased creatinine clearance) * currently enrolled in another hiv intervention study.

Keywords: pre-exposure prophylaxis hiv prevention mhealth stigma
randomized clinical trial of a pharmaceutical care program in chronic patients users of an emergency department

Conditions: Heart Failure; Pulmonary Disease, Chronic Obstructive

Summary: the study aims to assess the clinical and economic impact of a pharmaceutical care program initiated in the emergency department versus conventional follow-up of patients with decompensated heart failure/copd.

clinical trial aimed to assess the impact of a pharmaceutical care program initiated in the emergency department vs standard care in patients with heart failure and/or copd, conducted at the hospital de la santa creu i sant pau (barcelona, spain) between jan12-feb13. the researchers hypothesize that a systematic, standardized pharmaceutical care program may be related to a lower frequency of drug related problems (drp). moreover, the investigators also hypothesize that 6-month mortality, the average length of the hospital stay, and its related cost may also be decreased. this study was approved by the hospital de la santa creu i sant pau ethics committee. written informed consent will be obtained from the participants . the study will include 100 patients who fulfill all the inclusion criteria, described in the eligibility section.

Eligibility criteria:
inclusion criteria: * age: 65 years and over * admission in the emergency department for a period equal to or higher than 12 hours; * number of home medication equal to or higher than four; * diagnose in the emergency department episode: decompensated heart failure and/or decompensated copd. exclusion criteria: * suffering from dementia, severe mental disorders and living in nursing homes.

Keywords: pharmaceutical care emergency service
safety and immunogenicity study of 20vpnc when coadministered with a booster dose of bnt162b2

Conditions: Pneumococcal Disease; COVID-19; SARS-CoV-2 Infection

Summary: study of the safety and immunogenicity of 20vpnc and a booster dose of bnt162b2 administered at the same visit or each vaccine given alone


Eligibility criteria:
inclusion criteria: * male or female participants ≥65 years of age at the time of consent * participating or participated in study c4591001, received 2 doses of 30 µg bnt162b2 with the second dose given ≥6 months prior to the first vaccination in this study, and have not received a third dose of bnt162b2 * adults determined by clinical assessment, including medical history and clinical judgement, to be eligible for the study, including adults with preexisting stable disease * adults who have no history of ever receiving a pneumococcal vaccine, or received a licensed pneumococcal vaccination ≥12 months prior to the first vaccination in this study exclusion criteria: * history of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) * serious chronic disorder that in the investigator's opinion would make the participant inappropriate for entry into the study * previous clinical or microbiological diagnosis of covid-19 * previous vaccination with any investigational pneumococcal vaccine, or planned receipt of any licensed or investigational pneumococcal vaccine through study participation * previous vaccination with any coronavirus vaccine, other than those received in study c4591001 * other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study
washing pipe with a spray nozzle for topical anesthesia during bronchoscopy

Conditions: Pulmonary Disease

Summary: the goal of this randomized control trial is to evaluate the effectiveness and safety of using a spray nozzle, compared to the conventional method, for topical anesthesia by the spray-as-you-go technique in reducing cough frequency, improving cough, discomfort, tolerance, satisfaction, reducing the dosage of lidocaine consumption of patients during flexible bronchoscopy.


Eligibility criteria:
inclusion criteria: 1. age 18 years or older 2. a planned flexible bronchoscopy 3. being able to communicate with mandarin chinese or taiwanese hokkien exclusion criteria: 1. are unwilling to join the study 2. have tracheostomy or are intubated 3. will receive intravenous anesthesia during flexible bronchoscopy 4. known to be pregnant

Keywords: flexible bronchoscopy topical airway anesthesia
a prospective randomized study comparing the target volume for limited-stage small cell lung cancer

Conditions: Carcinoma of Lung; Small Cell; Limited Stage

Summary: we hypothesized that the local control for both arms were not statistically significant, when irradiation to the post-induction chemotherapy tumor volume is compared with irradiation to the pre-induction chemotherapy tumor volume.while elective nodal irradiation will be omitted for both arms.


Eligibility criteria:
inclusion criteria: * patients were eligible if they had histologic or cytologic verification of small cell lung cancer (sclc) and were radiographically confirmed limited-stage * patients with contralateral mediastinal and ipsilateral supraclavicular lymphadenopathy were also included. * the patients should be between 18 and 75 years old without previous thoracic radiotherapy, chemotherapy or biotherapy. * karnofsky performance status was ≥ 80. * forced expiratory volume at 1 second (fev1) ≥ 1 l. * had measurable or assessable disease. * neutrophilic granulocyte ≥ 1.5×109/l, haemoglobin ≥ 100 g/l, platelet count ≥ 100×109/l. * serum creatine and bilirubin \< 1.5 × the upper normal limit (unl), aminotransferase \< 2 × unl. * weight loss was less than 10% within 6 months before diagnosis. * written informed consent was required from all patients. exclusion criteria: * patients were ineligible if they had a history of other malignant diseases except for non-melanomatous skin cancer and carcinoma in situ of the cervix, or any contraindications for chemoradiotherapy, malignant pleural and/or pericardial effusion.
managing dysexecutive syndrome (ds): cihr 2011-2014

Conditions: Traumatic Brain Injury; Cerebrovascular Accident (CVA); Acquired Brain Injury

Summary: successful community participation following acquired brain injury (abi) continues to be an elusive goal for patients, clinicians and researchers. our pilot work shows that community dwelling survivors of abi can significantly improve performance on self-identified real- world performance problems and that they can transfer this learning to improve goals not trained in the treatment sessions. we will compare two types of rehabilitation intervention using a randomized controlled trial. we will also interview survivors, their significant others and clinicians regarding their experiences with each intervention to help us discover what works best.

executive dysfunction is endemic after severe acquired brain injuries (abis) and is highly associated with long-lasting psychosocial distress, problems in a multiplicity of everyday activities and overall reduced quality of life. there is increasing evidence to suggest that a novel behavioral intervention is a treatment of choice for executive dysfunction. however few studies have addressed ecological relevance: failing to take into account the significant impact of the complex settings of real life on executive function. more data are desperately needed in this area given the devastating consequences of abi. we propose to investigate the benefits of two community- based interventions.

Eligibility criteria:
inclusion criteria: * fluent in written and spoken english, * have sustained (1) a moderate to severe tbi as defined by a 6-hour gcs of 12 or less or (2) complicated mild tbi with gcs 13-15 and associated abnormal findings on ct or mri scan or (3) other form of acquired brain injury (abi) that is not related to a congenital, developmental or degenerative disorder but which occurred through a medical problem or disease process including stroke, exclusion criteria: other significant neurological or psychiatric history such as multiple sclerosis or psychiatric illness requiring hospitalization, concurrent moderate to severe depression.

Keywords: participation activities of daily living brain injuries executive function
efficacy of manual therapy techniques and electrotherapy modalities in individuals with non-specific low back pain

Conditions: Back Pain

Summary: low back pain is the fifth most common reason for doctor visits, affecting about 60-80% of people in their lifetime. despite this, there are not enough diagnostic and treatment methods in the literature to fully elucidate non-specific low back pain. in this case, the research showed that non-specific low back pain should be handled with a biopsychosocial approach, and its relationship with fascia and myofascial meridians should be investigated.

according holistic that approach patients with non-specific low back pain. instead of examining the problem of low back pain in the society only in the form of muscles, joints, ligaments, etc.; should evaluate low back pain over the fascia. it is seen that most studies in the literature only examine the painful area and tissue problems in its immediate vicinity, and therefore they approach low back pain with symptomatic treatment. in recent studies, however, the main problem is not limited to the painful area only; it has been determined that the tissue response caused by the problems in different parts of the body is transmitted to more distant regions via the fascia and myofascial meridians.

Eligibility criteria:
inclusion criteria: * being between the ages of 18-60 * volunteering to work * the person has a complaint of low back pain for more than 3 months * diagnosis of chronic low back pain by the doctor * being able to read and write and be cooperative. * not having received treatment for the lumbar region in the last 3 months * having an mri in the last 6 months. exclusion criteria: * not having any lumbar surgery or vertebral fracture * having neurological, radiculopathy, inflammatory, etc. disease * having spinal deformities such as scoliosis, kyphosis * having a vestibular or respiratory disorder * having auditory or cognitive impairment * medication that will affect the balance (sedatives, etc.) * patients with lower extremity amputation * those who want to quit working during the study period, those who do not attend regularly. * conditions such as cancer, infection, etc. in the spinal region

Keywords: manuel therapy
gardner packard healthy lifestyles program

Conditions: Childhood Obesity

Summary: gardner goals is a 6 month program for treatment of childhood obesity that consists of twice monthly telehealth meetings with a health educator. potential participants enter the study using a randomly ordered list of eligible patients based on bmi, age and number of clinic visits in 2020.

the gardner goals curriculum focuses on healthy eating and activity. the study participants are kids 6 to 14 years old with bmi ≥95th percentile who are patients at the gardner packard children's health center, a federally qualified health center. lessons contain educational materials and behavioral change strategies to promote healthy eating and physical activity and reduce screen time. patients are encouraged to continue routine clinic visits with their primary care physicians during the course of the study.

Eligibility criteria:
inclusion criteria: * bmi ≥ 95th percentile * two clinic visits in 2020 exclusion criteria: * signs of an eating disorder * moved out of town and not planning to return to gardner packard children's health center
safety and efficacy of agn 210669 ophthalmic solution in patients with ocular hypertension or primary open-angle glaucoma

Conditions: Ocular Hypertension; Glaucoma

Summary: the study will evaluate the safety and efficacy of agn-210669 ophthalmic solution in comparison with agn-210669 vehicle and bimatoprost ophthalmic solution dosed once-daily each morning, in subjects with ocular hypertension or primary open-angle glaucoma. subjects will be followed for 2 weeks.


Eligibility criteria:
inclusion criteria: * ocular hypertension or primary open-angle glaucoma * females of non-childbearing potential * subject requires iop-lowering therapy in both eyes * iop ≥ 22 mm hg and ≤ 34 mm hg * has a visual acuity score of 20/100 or better in each eye exclusion criteria: * uncontrolled systemic disease * active ocular disease * alteration of existing chronic systemic medications * known allergy or sensitivity to the study medications * ophthalmic corticosteroids * visual field loss which in the opinion of the investigator is functionally significant * history of ocular laser, intraocular surgery, or refractive surgery
mri superficial temporal artery

Conditions: Temporal Arteritis

Summary: repeat mri of the superficial temporal artery in 5 volunteers

repeat mri of the superficial temporal artery in 5 volunteers

Eligibility criteria:
inclusion criteria: * controls with normal temporal arteries exclusion criteria: * contraindication to mr
ultrathin des in complex pci scenarios: the ultra a multicenter study

Conditions: Coronary Artery Disease; Coronary Stenosis; Stent Restenosis; Left Main Coronary Artery Disease; Chronic Total Occlusion of Coronary Artery

Summary: ultra is a multicenter, observational, retrospective registry, enrolling consecutive patients treated with ultrathin coronary des (coronary stent with strut thickness \< 70 um) for coronary bifurcation lesions, left main disease, chronic total coronary occlusion, and in-stent restenosis regardless of their clinical presentation. target lesion failure (tlf a composite endpoint of cardiovascular death, target vessel myocardial infarction, target lesion revascularization and definite stent thrombosis) will be the primary end point, while its single components will be the secondary ones along with all-cause death, all acute myocardial infarction (excluding peri-procedural ami), target vessel revascularization and barc major bleedings (barc 3-5). due to the retrospective, observational nature of the registry, no formal sample size estimation is required. patients complying with detailed inclusion criteria and with a minimum follow up of 6 months will be enrolled.


Eligibility criteria:
inclusion criteria: * age \> 18 years old * unprotected left main stenosis * bifurcation coronary stenosis (with side branch diameter ≥ 2.5 mm) * chronic total coronary occlusion * in-stent restenosis treated with the following devices: * orsiro * mistent * biomime * supraflex cruz exclusion criteria: * patients died during the index revascularization procedure
imaging of vitreous opacities in a canadian population

Conditions: Floaters; Vitreous Opacities

Summary: the goal of this clinical trial is to capture imaging data of eye floaters in the population to build an imaging database to learn more about them in. participants will imaged with an investigational ophthalmic imaging device to capture images of their floaters.


Eligibility criteria:
inclusion criteria: * aged 18 years or older * symptomatic vitreous opacities (floaters) in vision * clear ocular media, to allow a clear view of the vitreous for the svo-id exclusion criteria: * younger than 18 years of age * presence of vitreous hemorrhage * cataract grade 3 and above * opacification of lens, cornea, or vitreous * diagnosis of narrow angle glaucoma * refractive error is outside the range of -6d to+3d * astigmatism is outside the range of +/-2d of cylinder
downhill walking training in copd

Conditions: Pulmonary Disease, Chronic Obstructive

Summary: this randomized control trial will investigate whether a modality that generates more contractile muscle fatigue with lower ventilatory requirements render better results after a 12-week exercise training program in subjects with copd. subjects will be randomized to either exercise in a training program including downhill walking or to exercise in a training program including conventional walking.


Eligibility criteria:
inclusion criteria: * patients with a primary diagnosis of copd according to internationally accepted guidelines * patients referred to the outpatient pr program of gasthuisberg university hospital(leuven, belgium) exclusion criteria: * any underlying disease or musculoskeletal limitation that could impair the ability to perform any of the exercise training modalities * absence of exacerbations in the previous month before entering the present study * patients included on the waiting list for lung transplantation

Keywords: pulmonary disease, chronic obstructive downhill walking exercise
exploring stress and coping behaviors of the major carer whose children with prader-willi syndrome

Conditions: Prader-Willi Syndrome

Summary: ask the 4 carers of children with prader-willi syndrome to disclose their experiences and difficulties for searching better management and intervention


Eligibility criteria:
inclusion criteria: * a person who care and live with children with prader-willi syndrome exclusion criteria: * siblings or less-contact family * teachers

Keywords: stress carer's experiences prader-willi syndrome personal experiences